SNG001 
GtoPdb Ligand ID: 11129
Compound class:
Peptide
Comment: SNG001 is a recombinant form of human interferon β, interferon beta-1a, in a formulation that can be administered via a neubliser, directly to the lungs. Synairgen originally developed SNG001 as a therapy for virally-induced exacerbations of COPD, but have rapidly re-deployed it for SARS-CoV-2 infection. The EU Clinical Trials Register entry for Synairgen's study of SNG001 in COVID-19 patients (EudraCT Number: 2020-001023-14) contains the detail that SNG001 is "Interferon beta-1a".
|
For advanced searching click here to open chemical structure editor
Other Similar Sequences  |
|
| IFN-β {Sp: Human} |
TargetsInterferon-α/β receptor; interferon α/β receptor 1 |
| peginterferon beta-1a | |
| IFN-β1a (recombinant human) | |
| IFN-β1b (recombinant human) | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License